Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).
Alpha1-proteinase inhibitor (human) 1000mg/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free. Upper respiratory tract infection, UTI, nausea, pain, chills, cough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback